Search

Displaying results 2931 - 2940 of 7497 in total
  1. Drug

    Sulfadimethoxine

    go.drugbank.com/drugs/DB06150
    ApprovedVet approvedWithdrawn

    It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.[L43942]

    Synonyms: N(1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
  2. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [DB00811] depending on the the presence of resistance associated amino acid substitutions

  3. Drug

    Prostaglandin G2

    go.drugbank.com/drugs/DB03866
    Experimental

    A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]

  4. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    [A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823] … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  5. Drug

    Atovaquone

    go.drugbank.com/drugs/DB01117
    ApprovedInvestigational

    Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.

  6. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.

  7. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  8. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.

  9. Drug

    Gaboxadol

    go.drugbank.com/drugs/DB06554
    Investigational

    It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives. … Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing

  10. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.

    Categories: Analgesics, Non-Narcotic, Agents to Treat Airway DiseaseSynonyms: N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea